In this issue:
Dual targeted CAR T cells blocking fibroblasts may overcome resistance
Anti-BCMA CAR T cell therapy is safe and effective regardless of ECOG PS
Multi-antigen targeted (BCMA /CD19) CAR T cell therapy promising
Examination of response kinetics to daratumumab-based treatment
Pre-treatment serum IL-6 predicts carfilzomib-induced hypertension
Real-world outcomes in MGRS
Guidance for use and dosing of selinexor in MM
MRD and imaging-guided consolidation strategies
A machine learning model predicts undetectable MRD and survival outcomes
VTE risk with VRd induction
Please login below to download this issue (PDF)